Nicklas Westerholm, CEO
Nicklas Westerholm, b. 1976, has since 1995 been working in the AstraZeneca Group in several global roles and different business areas, most recently as Vice President Project & Portfolio Management, Cardiovascular and Metabolic Diseases, Global Medicines Development Unit. Prior positions include roles as Executive Officer and Vice President of Japan Operations, Director Investor Relations, Head of Global API Supply and Head of Development Manufacture. Nicklas Westerholm has studied analytical and organic chemistry at Stockholm University, and Chemical Engineering at KTH Royal Institute of Technology. He has also participated in educational programs at the University of Warwick, INSEAD and Harvard Business School.
Jacques Näsström, Vice president pre clinical R&D/Chief Scientific Advisor
Jacques Näsström has a basic training as Pharmacist with PhD in Pharmacology from Uppsala University and a Business degree from Stockholm School of Economics. He has over 30 years of experience from the pharmaceutical and biotechnology industries, including a position as Investment Manager at Karolinska Investment Fund, and various positions within drug discovery at Astra and AstraZeneca and as Director of Research & Development at Q-Med AB from 2006-2010.
Marie Bengtson, Clinical Project Director
Marie Bengtson has more than 20 years of clinical development experience within the pharmaceutical industry. This experience includes the international research companies Merck-Serono and Sanofi-Aventis, and the contract research organization, Quintiles. Marie has considerable experience of project management, planning, execution and reporting of clinical trials within cancer, cardiovascular diseases, diabetes, and diseases in the nervous system. She has been involved in early as well as late clinical trials. Moreover, she has 17 years of background as an operating room nurse as well as a diploma in marketing, DIHM, from IHM Business School.
Michaela Gertz, CFO
Michaela Gertz has a basic training from Uppsala University and Katholieke Universiteit in Belgium with a master degree in Business. She has experience in the financial industry and small life science companies and has previously been working for Svenska Handelsbanken, Avanza, ITP Invest and as analyst and IR manager at Accelerator Nordic AB. Michaela Gertz is in addition to CFO also responsible for investor relations and communication at PledPharma AB.
Sven Jacobsson, CMC
Sven has PhD in Analytical chemistry and is a senior advisor in Chemistry, Manufacturing and Control (CMC). Sven is Visiting Professor at Stockholm University and founder of BioPharmaLinx AB and ClinStorage AB and he has more than 30 years of experience from the pharmaceutical industry and has held Senior Management and Director positions at Kabi, Pharmacia and AstraZeneca.
Malin Nittve, Project Manager and Director of Regulatory Affairs
Malin Nittve is a pharmacist and holds an MBA. She has over 25 years of diverse experience ranging from small start up companies to large international pharmaceutical companies. Malin has worked primarily in product development, project management and regulatory affairs at the Karolinska Hospital (Innovation Centre), Melacure, Biolipox, Pharmacia, Linde Healthcare, and from her consulting company Pro Saludis. Malin has extensive and proven strategic regulatory expertise (EMEA and FDA), experience of project management and product development of pharmaceutical and biological therapies, including cell therapy and medical devices. Moreover Malin interpersonal experience from both small biotechnology companies and large pharmaceutical companies.
James Van Alstine, IP Advisor
James Van Alstine holds a B. Sc. in Biochemistry and a Ph. D. in Pathology from the University of British Columbia in Vancouver. He had a long academic career as a professor in the United States (Biomaterials, University of Alabama System – NSF and NASA funding) and Sweden (Biotechnology, Royal Inst. of Technology – VR funding) before joining General Electric Healthcare (GEHC) in 2000. Over the next 14 years with GEHC he undertook a number of duties including Academic Alliance Coordination, Project Management, and New Technology Innovation. He is listed as an author on 80+ scientific papers and co-inventor on 50+ patents spread over 25 patent groups.
Dennis Henriksen, Project Manager Aladote
Dennis Henriksen holds a M.Sc. in chemical engineering from the Technical University of Copenhagen and a Ph.D. in bioorganic chemistry from the University of Copenhagen.
Dennis B. Henriksen M.Sc., PhD., has 20+ years managerial industry experience from small to medium size biotechnology companies, including several years in the United States as Vice President in BioNebraska Inc. where he also served as a member in the corporate management group and was responsible for R&D.
Key positions Partner in Ventac Partners, Vice President in Nordic Bioscience A/S, COO in Verigen Europe A/S, Vice President in Osteometer Biotech, Managing Director in BION, Vice President in BioNebraska and Dennis Henriksen was the founder and CEO of Sanos Bioscience A/S from the formation in 2004 of the company until the company was sold in 2010.
Dennis Henriksen are providing a broad set of services to biotechnology companies, including preparation of business plans, clinical development and regulatory strategy, technology assessment, In/out-licensing negotiations, managing outsourcing operations, IP activities, fundraising and management presentations.